IDEXX Laboratories (NASDAQ:IDXX) updated its FY 2017 earnings guidance on Thursday. The company provided EPS guidance of $4.61-4.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.83. The company issued revenue guidance of $2.385-2.425 billion, compared to the consensus revenue estimate of $2.45 billion.IDEXX Laboratories also updated its FY 2018 guidance to $4.16-4.21 EPS.
NASDAQ IDXX opened at $212.12 on Thursday. IDEXX Laboratories has a 12 month low of $146.09 and a 12 month high of $256.22. The stock has a market cap of $18.20 billion, a PE ratio of 64.67, a P/E/G ratio of 1.92 and a beta of 0.64.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Wednesday, August 1st. The company reported $1.23 EPS for the quarter, beating the Zacks’ consensus estimate of $1.17 by $0.06. IDEXX Laboratories had a net margin of 14.50% and a negative return on equity of 703.80%. The company had revenue of $580.75 million during the quarter, compared to the consensus estimate of $574.68 million. During the same quarter in the prior year, the company posted $0.87 EPS. The company’s quarterly revenue was up 14.1% compared to the same quarter last year. Sell-side analysts forecast that IDEXX Laboratories will post 4.18 earnings per share for the current year.
IDXX has been the subject of a number of research analyst reports. BidaskClub downgraded shares of IDEXX Laboratories from a strong-buy rating to a buy rating in a research note on Tuesday, September 11th. Zacks Investment Research downgraded shares of IDEXX Laboratories from a buy rating to a hold rating in a research note on Monday, July 9th. Stifel Nicolaus upped their price objective on shares of IDEXX Laboratories from $225.00 to $260.00 and gave the company a buy rating in a research note on Tuesday, July 10th. Credit Suisse Group upped their price objective on shares of IDEXX Laboratories from $255.00 to $259.00 and gave the company an outperform rating in a research note on Friday, August 17th. Finally, Piper Jaffray Companies upped their price objective on shares of IDEXX Laboratories to $236.00 and gave the company an overweight rating in a research note on Wednesday, August 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $244.00.
In other news, Chairman Jonathan W. Ayers sold 30,000 shares of the business’s stock in a transaction dated Thursday, August 23rd. The stock was sold at an average price of $245.50, for a total transaction of $7,365,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Jacqueline Studer sold 8,598 shares of the business’s stock in a transaction dated Monday, August 6th. The stock was sold at an average price of $242.37, for a total value of $2,083,897.26. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 70,129 shares of company stock valued at $17,159,219. Corporate insiders own 2.56% of the company’s stock.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Further Reading: Stock Symbols and CUSIP Explained
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.